Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
-
Publication number: 20130195944Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Publication number: 20130197035Abstract: Disclosed herein are surgical adjuvant compositions for ameliorating tissue and cellular necrosis and/or apoptosis. In addition, surgical methods are described which include the use of the adjuvant of the composition to reduce tissue and cellular necrosis and/or apoptosis.Type: ApplicationFiled: March 12, 2013Publication date: August 1, 2013Inventors: Ian K.Y. Lo, Paul Sciore, Ken Muldrew
-
Publication number: 20130195883Abstract: The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.Type: ApplicationFiled: September 7, 2010Publication date: August 1, 2013Applicants: THE UNIVERSITY OF BIRMINGHAM, BIOTIE THERAPIES CORP.Inventors: Christopher Weston, Lee Charles Claridge, David Adam, David Smith, Nina Westerlund, Marjo Pihlavisto, Thua Österman
-
Publication number: 20130197003Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: GALDERMA LABORATORIES, INC.Inventor: GALDERMA LABORATORIES, INC.
-
Publication number: 20130196849Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.Type: ApplicationFiled: January 27, 2012Publication date: August 1, 2013Applicant: Celanese Acetate LLCInventors: Michael T. Combs, Thomas S. Garrett
-
Patent number: 8491931Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.Type: GrantFiled: September 30, 2009Date of Patent: July 23, 2013Assignee: Norgine BVInventors: Norman Barras, Jeffrey Martin Thompson
-
Publication number: 20130177651Abstract: This invention relates to a pharmaceutical composition suitable for use in a dry powder inhaler comprising: (i) carrier particles; (ii) active particles on the surface of the carrier particles; and (iii) excipient on the surface of the carrier particles, wherein the excipient comprises phytosterol, phytosterol derivative, phytostanol, phytostanol derivative or combinations thereof. This invention relates to a method of applying the excipient particles onto the carrier particles.Type: ApplicationFiled: September 5, 2011Publication date: July 11, 2013Applicant: PHARMATERIALS LIMITEDInventor: Bildad Kimani Nyambura
-
Publication number: 20130172297Abstract: Disclosed is the use of a compound of formula I wherein X is O, S, SO or SO2; R1 is halogen, trihalomethyl, —OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH2—OH, —CH2—CH2—OH, C1-4alkylthio, C1-4alkyl-sulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy; R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy; R3H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl; each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen; and n is an integer from 1 to 4; or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, CType: ApplicationFiled: May 5, 2011Publication date: July 4, 2013Applicant: NOVARTIS AGInventors: Peter Gergely, Erik Wallstroem
-
Publication number: 20130172359Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: February 25, 2013Publication date: July 4, 2013Applicant: GALDERMA LABORATORIES INC.Inventor: Galderma Laboratories Inc.
-
Patent number: 8476305Abstract: A novel therapeutic agent or prophylactic agent for an inflammatory bowel disease is provided. An amino alcohol derivative represented by the general formula (1): which is a sphingosine-1-phosphate receptor agonist or a pharmaceutically acceptable salt or hydrate thereof are a therapeutic agent or prophylactic agent for an inflammatory bowel disease comprises.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Naoya Yamamuro, Koichi Nakamaru, Tokutarou Yasue
-
Publication number: 20130165371Abstract: A spray-drying apparatus includes a drying chamber that has a first end, a second end, and at least one side wall extending between the first and second ends to define an interior of the drying chamber having a center axis. A nozzle can be positioned at the first end of the drying chamber and be configured to atomize liquid and spray the atomized liquid into the interior of the drying chamber at a maximum spray pattern angle relative to the center axis. A heating device can be provided to heat the liquid prior to introduction into the drying chamber.Type: ApplicationFiled: September 1, 2011Publication date: June 27, 2013Applicant: BEND RESEARCH, INC.Inventors: Daniel E. Dobry, James M. Mullin, Douglas L. Millard, Dwayne T. Friesen, David D. Newbold, John M. Baumann, Devon B. Dubose
-
Publication number: 20130165470Abstract: The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.Type: ApplicationFiled: December 19, 2012Publication date: June 27, 2013Applicant: THE PROCTER & GAMBLE COMPANYInventor: THE PROCTER & GAMBLE COMPANY
-
Publication number: 20130157925Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.Type: ApplicationFiled: December 3, 2012Publication date: June 20, 2013Inventor: Young Hee Ko
-
Publication number: 20130149388Abstract: Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is a serious and growing public health concern. The major environmental risk factor for COPD is cigarette smoking, but the biological mechanisms underlying COPD are not well understood. Herein, proton nuclear magnetic resonance (1H-NMR) spectroscopy is used in methods to identify metabolites and biomarkers associated with lung function in COPD.Type: ApplicationFiled: July 3, 2012Publication date: June 13, 2013Inventors: Joseph Louie MCCLAY, Barbara K. ZEDLER, Edward Lenn MURRELLE, Edwin J.C.G. VAN DEN OORD, Thomas O'CONNELL, Daniel ADKINS
-
Publication number: 20130150311Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.Type: ApplicationFiled: December 13, 2011Publication date: June 13, 2013Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
-
Publication number: 20130150454Abstract: Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.Type: ApplicationFiled: November 29, 2012Publication date: June 13, 2013Applicant: ALS THERAPY DEVELOPMENT INSTITUTEInventor: ALS THERAPY DEVELOPMENT INSTITUTE
-
Publication number: 20130144250Abstract: A method of treatment, such as treating an estrogen-related disorder or a psychotic disorder, by implanting a reservoir-based drug delivery composition into a subject to systemically deliver a therapeutically effective amount of an active pharmaceutical ingredient (such as an aromatase inhibitor or risperidone) to the subject for a long period of time (e.g., one month or one year). The drug delivery composition may include a rate-controlling excipient (e.g., an elastomeric polymer) defining a reservoir containing at least one discrete solid dosage form (e.g., one or more pellets), which includes an active pharmaceutical ingredient and optionally, a sorption enhancer.Type: ApplicationFiled: October 24, 2012Publication date: June 6, 2013Applicant: Endo Pharmaceuticals Solutions Inc.Inventor: Endo Pharmaceuticals Solutions Inc.
-
Patent number: 8445542Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.Type: GrantFiled: November 29, 2012Date of Patent: May 21, 2013Assignee: Bridge Pharma, Inc.Inventor: A. K. Gunnar Aberg
-
Publication number: 20130123366Abstract: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.Type: ApplicationFiled: November 1, 2012Publication date: May 16, 2013Applicant: The Ohio State University Research FoundationInventor: The Ohio State University Research Foundation
-
Publication number: 20130123172Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.Type: ApplicationFiled: December 20, 2012Publication date: May 16, 2013Applicant: DIAPIN THERAPEUTICS LLCInventor: DIAPIN THERAPEUTICS LLC
-
Patent number: 8440863Abstract: The present invention relates to an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.Type: GrantFiled: February 15, 2012Date of Patent: May 14, 2013Assignee: Janssen Pharmaceutica, NVInventors: Walter Ferdinand Maria Filliers, Rudy Laurent Maria Broeckx
-
Patent number: 8435497Abstract: The invention relates to pharmaceutical compositions containing combinations of formoterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.Type: GrantFiled: June 9, 2004Date of Patent: May 7, 2013Assignee: Takeda GmbHInventors: Klaus Dietzel, Helgert Mueller
-
Publication number: 20130109674Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.Type: ApplicationFiled: December 17, 2010Publication date: May 2, 2013Applicant: Achelios Therapeutics LLCInventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
-
Publication number: 20130104881Abstract: Pharmaceutical pressurized metered dose inhalers are disclosed having improved temperature and moisture stability comprising CFC-free, ethanol-free compositions that include lactose of particle diameter larger than 1 ?m as a means of minimizing sticking to the walls and other destabilization mechanisms activated by moisture ingress from the environment.Type: ApplicationFiled: October 31, 2011Publication date: May 2, 2013Applicant: Laboratorio Pablo Cassara S.R.L.Inventors: Fernando Toneguzzo, Julio Cesar Vega
-
Publication number: 20130102683Abstract: The invention relates to methods including the step of joint melt processing of (i) fingolimod or a pharmaceutically acceptable salt thereof, with (ii) a matrix former into an intermediate, intermediates obtainable in this way, and oral dosage forms, especially tablets, containing the intermediates of the invention. The invention further relates to a method of preparing the dosage forms of the invention, especially tablets. Finally, the invention relates to oral dosage forms for the treatment of multiple sclerosis.Type: ApplicationFiled: April 21, 2011Publication date: April 25, 2013Applicant: RATIOPHARM GMBHInventors: Jana Paetz, Sandra Brueck
-
Publication number: 20130102682Abstract: The invention relates to an intermediate containing fingolimod and matrix material, wherein the fingolimod is present in the matrix material in the form of a solid solution. The invention also relates to granules and pharmaceutical formulations containing fingolimod in the form of a solid solution in matrix material. The subject matter of the invention further relates to methods of preparing a solid solution of fingolimod or of an intermediate, and also granules and pharmaceutical formulations containing fingolimod in the form of a solid solution.Type: ApplicationFiled: April 21, 2011Publication date: April 25, 2013Applicant: Ratiopharm GMBHInventors: Jana Paetz, Dominique Meergans
-
Publication number: 20130095156Abstract: The invention provides disintegratable films containing a mixture of high molecular weight and low molecular weight water soluble components; and a pharmaceutically or cosmetically active ingredient. Optionally, the films contain a starch component, a glucose component, a filler, a plasticizer and/or humectant. The films are preferably in the form of a mucoadhesive monolayer having a thickness sufficient to rapidly disintegrate in the oral environment and release the active ingredient without undue discomfort to the oral mucosa. The monolayer can be cut to any desired size or shape to provide conveniently useable unit dosage forms for administration to oral or other mucosal surfaces for human pharmaceutical, cosmetic, or veterinary applications. The invention further provides methods of administering the film compositions by placing the composition into, for example, the oral cavity for a sufficient period of time to permit the film to disintegrate and release the active ingredient.Type: ApplicationFiled: December 10, 2012Publication date: April 18, 2013Applicant: Adhesives Research, Inc.Inventor: Adhesives Research, Inc.
-
Publication number: 20130096126Abstract: A method for enhancing learning or memory of both in a mammal having impaired learning or emory of both from a neuro-degenerative disorder, which entails the step of administering at least one compound or a salt thereof which is a ?1-adrenergic receptor agonist, partial agonist or receptor ligand in an amount effective to improve the learning or memory or both of said mammal.Type: ApplicationFiled: April 22, 2011Publication date: April 18, 2013Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Mehrdad Shamloo, Mehrdad Faizi, William Mobley
-
Publication number: 20130095177Abstract: The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form containing fingolimod and accordingly intermediates, granules and oral dosage forms obtainable by that method.Type: ApplicationFiled: April 21, 2011Publication date: April 18, 2013Applicant: RATIOPHARM GMBHInventors: Jana Paetz, Katrin Rimkus
-
Patent number: 8420625Abstract: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.Type: GrantFiled: April 28, 2011Date of Patent: April 16, 2013Assignee: Lithera, IncInventor: John Daniel Dobak
-
Publication number: 20130090295Abstract: A method of promoting or improving the feed efficiency and the muscle to fat ratio in animals by administering to the animals a therapeutically effective amount of a pure or substantially pure RR-isomer of ractopamine is disclosed. Also disclosed are animal feed preparations and compositions and pharmaceutical preparations capable of increasing lean meat deposition in an animal or decreasing body fat, or promoting or improving the growth of an animal or improving the feed efficiency of an animal. Feed preparation, compositions and pharmaceutical preparations including therapeutically effective amounts of a pure or substantially pure RR-isomer of ractopamine are disclosed.Type: ApplicationFiled: November 29, 2012Publication date: April 11, 2013Applicant: BRIDGE PHARMA, INC.Inventor: BRIDGE PHARMA, INC.
-
Patent number: 8415397Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: GrantFiled: April 8, 2011Date of Patent: April 9, 2013Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Publication number: 20130084343Abstract: Methods of sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more RNAs associated with sepsis are also provided. Compositions and kits are also provided.Type: ApplicationFiled: September 14, 2012Publication date: April 4, 2013Applicant: CEPHEIDInventors: David Vilanova, Olivier Delfour
-
Publication number: 20130084340Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark Tengler, Paul Taskey, Daniel Lockhart, Russell McMahen
-
Publication number: 20130079344Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.Type: ApplicationFiled: March 14, 2012Publication date: March 28, 2013Applicant: OMEROS CORPORATIONInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Publication number: 20130079309Abstract: The invention provides methods for treating or reducing the risk of developing acute lung injury manifested by increased vascular permeability. Also provided are pharmaceutical compositions comprising an FTY720 analog or derivative and/or SEW 2871 for use in the disclosed methods. The invention also provides methods for treating or reducing the risk of developing acute lung injury resulting from dysregulation of ceramide/sphingolipid pathway, more specifically, acute lung injury resulting from radiation.Type: ApplicationFiled: March 3, 2011Publication date: March 28, 2013Applicant: The Board of Trustees of the University of IllinoisInventors: Joe G.N. Garcia, Steven M. Dudek
-
Publication number: 20130074834Abstract: A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.Type: ApplicationFiled: November 21, 2012Publication date: March 28, 2013Applicant: CIPLA LIMITEDInventor: Cipla Limited
-
Publication number: 20130072567Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastro-intestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.Type: ApplicationFiled: November 15, 2012Publication date: March 21, 2013Applicant: NORGINE BVInventor: Norgine BV
-
Publication number: 20130071440Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: ApplicationFiled: August 17, 2012Publication date: March 21, 2013Applicant: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Publication number: 20130065954Abstract: The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder.Type: ApplicationFiled: November 8, 2012Publication date: March 14, 2013Applicant: NOVARTIS AGInventor: NOVARTIS AG
-
Publication number: 20130065885Abstract: The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system.Type: ApplicationFiled: September 14, 2012Publication date: March 14, 2013Applicant: IMAGINOT PTY LTD.Inventors: Michael Stephen Roberts, Ruoying Jiang, Keivan Bezanehtak, Greg Andrew Davey, George Alexander Davidson, Geraldine Ann Elliott, Stephen Douglas Chandler, Mantu Sarkar
-
Publication number: 20130059821Abstract: Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors.Type: ApplicationFiled: September 10, 2012Publication date: March 7, 2013Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
-
Patent number: 8383685Abstract: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.Type: GrantFiled: September 8, 2011Date of Patent: February 26, 2013Assignee: Bridge Pharma, Inc.Inventor: A. K. Gunnar Aberg
-
Patent number: 8383681Abstract: The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof.Type: GrantFiled: May 7, 2008Date of Patent: February 26, 2013Assignee: Chelsea Therapeutics, Inc.Inventors: Michael J. Roberts, Simon Pedder
-
Patent number: 8372888Abstract: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting survival signaling in cancer cells, and reducing symptoms of multiple sclerosis.Type: GrantFiled: April 29, 2009Date of Patent: February 12, 2013Assignee: Enzo Therapeutics, Inc.Inventors: Robert E. Zipkin, Sarah Spiegel, Jeffrey Kroll Adams
-
Patent number: 8367734Abstract: A stable suspension aerosol formulation of epinephrine is suitable for administration through inhalation comprising a therapeutically effective amount of epinephrine, hydrofluorocarbon propellant, co-solvent, surfactant, and antioxidant. The suspension aerosol formulation further comprises [pre-] pre-micronized epinephrine suspended in an alcohol/surfactant solution with hydrofluoroalkane propellant. The suspension formulation provides a highly efficient delivery of drug microparticles into the respirable region of patients' lungs and has the following advantages: lower dosage requirement, minimum alcohol content, with less impurities generated during storage, improved efficacy and safety, and exhibits no ozone depleting potential compared to a formulation containing chlorofluorocarbon.Type: GrantFiled: May 7, 2010Date of Patent: February 5, 2013Assignee: Amphastar Pharmaceuticals Inc.Inventors: Jianxin Gao, James Luo, Rong Zhou, Mary Ziping Luo, Jack Yongfeng Zhang
-
Publication number: 20130028845Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.Type: ApplicationFiled: October 2, 2012Publication date: January 31, 2013Applicant: Sunovion Pharmaceuticals Inc.Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
-
Publication number: 20130028977Abstract: The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject.Type: ApplicationFiled: March 30, 2011Publication date: January 31, 2013Applicant: GLENMARK PHARMACEUTICALS LIMITEDInventors: Ulhas Dhuppad, Sunil Sudhakar Chaudhari
-
Publication number: 20130022654Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.Type: ApplicationFiled: February 7, 2011Publication date: January 24, 2013Applicant: LUPIN LIMITEDInventors: Ashish Ashokrao Deshmukh, Pravin Meghrajji Bhutada, Sajeev Chandran, Shirishkumar Kulkarni
-
Publication number: 20130017190Abstract: The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720.Type: ApplicationFiled: August 6, 2012Publication date: January 17, 2013Inventor: Betty C. Soliven